Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

NCT01905813 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Malignancies

Interventions

DRUG: INCB040093
DRUG: INCB040093 + itacitinib

Sponsor

Incyte Corporation